Germany · Delayed Price · Currency is EUR bioXXmed AG Statistics
Total Valuation
bioXXmed AG has a market cap or net worth of EUR 277,302. The enterprise value is 389,302.
| Market Cap | 277,302 |
| Enterprise Value | 389,302 |
Important Dates
The next estimated earnings date is Tuesday, December 22, 2026.
| Earnings Date | Dec 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
bioXXmed AG has 271,865 shares outstanding.
| Current Share Class | 271,865 |
| Shares Outstanding | 271,865 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -1,030.86 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 151.33
| Current Ratio | 151.33 |
| Quick Ratio | 92.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.92 |
Financial Efficiency
Return on equity (ROE) is -585.37% and return on invested capital (ROIC) is -18.27%.
| Return on Equity (ROE) | -585.37% |
| Return on Assets (ROA) | -14.04% |
| Return on Invested Capital (ROIC) | -18.27% |
| Return on Capital Employed (ROCE) | -18.94% |
| Weighted Average Cost of Capital (WACC) | 14.86% |
| Revenue Per Employee | -135 |
| Profits Per Employee | -92,195 |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -92 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +70.00% in the last 52 weeks. The beta is 5.12, so bioXXmed AG's price volatility has been higher than the market average.
| Beta (5Y) | 5.12 |
| 52-Week Price Change | +70.00% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 55.96 |
| Average Volume (20 Days) | 67 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, bioXXmed AG had revenue of EUR -269 and -184,390 in losses.
| Revenue | -269 |
| Gross Profit | -269 |
| Operating Income | -85,228 |
| Pretax Income | -184,482 |
| Net Income | -184,390 |
| EBITDA | -85,218 |
| EBIT | -85,228 |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 273,000 in cash and 385,000 in debt, with a net cash position of -112,000 or -0.41 per share.
| Cash & Cash Equivalents | 273,000 |
| Total Debt | 385,000 |
| Net Cash | -112,000 |
| Net Cash Per Share | -0.41 |
| Equity (Book Value) | n/a |
| Book Value Per Share | n/a |
| Working Capital | 451,000 |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 10 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | 31,683.27% |
| Pretax Margin | 68,580.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
bioXXmed AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -66.49% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 14, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jan 14, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
bioXXmed AG has an Altman Z-Score of -134.29 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -134.29 |
| Piotroski F-Score | 1 |